Merck KGaA agrees to acquire Silence Therapeutics for $20 per ADS in cash

Merck KGaA has agreed to acquire Silence Therapeutics, a U.K. biotech, for $20 per American Depositary Share in cash, valuing the deal at about $1.3 billion.

Detected & updated continuously · Source: Nebula